HK$105.80
15.00%
Hong Kong, Sep 29, 03:52 pm HKT. Closed.
Why the stock moved Why the stock moved Beta
ISIN
KYG0146B1032
Symbol
9926

Akeso Inc Stock price

HK$106.30
+16.40 18.24% 1M
-26.80 20.14% 6M
-6.70 5.93% YTD
-28.60 21.20% 1Y
+70.30 195.28% 3Y
+64.60 154.92% 5Y
+82.00 337.45% 10Y
+82.00 337.45% 20Y
Hong Kong, Closing price Tue, Sep 29 2026
+14.30 15.54%
ISIN
KYG0146B1032
Symbol
9926
Industry

Is Akeso Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,127 stocks worldwide.

Key metrics

Basic
Market capitalization
HK$86.2b
Enterprise Value
HK$81.3b
Net debt
positive
Cash
HK$10.7b
Shares outstanding
921.1m
Valuation (TTM | estimate)
P/E
negative
P/S
21.4 | 15.4
EV/Sales
20.2 | 14.6
EV/FCF
-
P/B
8.7
Financial Health
Equity Ratio
56.6%
Return on Equity
-12.3%
ROCE
-6.0%
ROIC
-15.4%
Debt/Equity
0.6
Financials (TTM | estimate)
Revenue
HK$4.0b | HK$5.6b
EBITDA
-
EBIT
HK$-930.6m
Net Income
HK$-1.1b
Free Cash Flow
-
Growth (TTM | estimate)
Revenue
37.4% | 56.3%
EBITDA
-
EBIT
5.0%
Net Income
-14.3%
Free Cash Flow
-
Margin
Gross
75.4%
EBITDA
-
EBIT
-23.1%
Net
-28.0%
Free Cash Flow
-
More
EPS
HK$-1.2
FCF per Share
-
Short interest
-
Employees
4k
Rev per Employee
HK$950.0k

Akeso Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

31 Analysts have issued a Akeso Inc forecast:

29x Buy
94%
2x Hold
6%

Analyst Opinions

31 Analysts have issued a Akeso Inc forecast:

Buy
94%
Hold
6%

Financial data from Akeso Inc

Jun '26
+/-
%
4,034 4,034
37% 37%
100%
- Direct Costs 991 991
63% 63%
25%
3,043 3,043
31% 31%
75%
- Selling and Administrative Expenses 2,202 2,202
35% 35%
55%
- Research and Development Expense 1,902 1,902
23% 23%
47%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -931 -931
5% 5%
-23%
Net Profit -1,131 -1,131
14% 14%
-28%

In millions HKD.

Don't miss a Thing! We will send you all news about Akeso Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Akeso, Inc. Is an investment company, which engages in the research and development, production, and sale of biopharmaceuticals products. The company is headquartered in Zhongshan, Guangdong and currently employs 3,529 full-time employees. The company went IPO on 2020-04-24. The Company’s programs covering the therapeutic areas of oncology, autoimmune and metabolic diseases. The firm's products mainly include cadonilimab (PD-1/CTLA-4), ivonescimab (PD-1/VEGF), Ligufalimab (AK117, CD47), Pulocimab (AK109, VEGFR-2), ANNIKO (penpulimab, PD-1), and tagitanlimab (PD-L1) used in oncology fields as well as ebronucimab (PCSK9), ebdarokimab (IL-12/IL-23), and Gumokimab (AK111, IL-17) used in metabolic and autoimmune therapeutic fields.

Head office Cayman Islands
CEO Dr. Xia
Employees 3,761
Website www.akesobio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today